GlobeNewsWire
02 Aug 2026, 16:10 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
FDA staff reviewers raised concerns regarding the effectiveness data of Capricor Therapeutics' cell therapy (deramiocel) for a Duchenne muscular dystrophy-related heart condition. — FDA skepticism regarding core product effectiveness is a primary catalyst for severe valuation drops in biotech companies.
-0.90The Rosen Law Firm has initiated an investigation into potential securities claims against Capricor Therapeutics following allegations of materially misleading business information. — Class action investigations create additional legal liability and overhead, though they often follow the initial price collapse.
-0.30Which stocks this story touches
The company faces a potential class action lawsuit following an FDA data concern that caused shares to plunge 65%.
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is mentioned in the context of a securities law firm reminding purchasers of a potential legal action.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
